ChinaDrugStatus

Sacituzumab tirumotecan

芦康沙妥珠单抗
Brand: 佳泰莱·Oncology·Last verified 2026-11-20

TROP2-directed ADC whose 2026 NRDL payment scope expands from 2 to 4 indications, adding HR+/HER2- breast cancer and earlier post-TKI EGFR-mutant NSCLC.

China Approval (NMPA)

Approved
Approval Number(s)
国药准字S20240052
Initial Approval Date
Nov 27, 2024
Notice Published
Nov 27, 2024
MAH
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (四川科伦博泰生物医药股份有限公司)
Approved Scope
Adult patients with unresectable locally advanced or metastatic triple-negative breast cancer (TNBC) who have received at least two prior systemic therapies (at least one in the advanced or metastatic setting).

National Reimbursement

Announced · Effective Jan 1, 2027
2026 Edition Entry
Negotiated #284 · Class B
Agreement Period
2027-01-01 to 2027-12-31
Payment Standard
* Confidential (marked with asterisk in NHSA PDF)
2026 Payment Scope
Expanded to 4 indications: (1) ≥3L TNBC; (2) HR+/HER2- unresectable/metastatic BC post-ET and ≥1L chemo; (3) EGFR-mutated non-squamous NSCLC post-EGFR-TKI and platinum chemo; (4) Earlier-line EGFR-mutated non-squamous NSCLC post-EGFR-TKI alone.
限:1.既往至少接受过2种系统治疗的不可切除局部晚期或转移性三阴性乳腺癌成人患者;2.既往接受过内分泌治疗且在晚期阶段接受过至少一线化疗的不可切除或转移性HR阳性HER2阴性(IHC 0、1+或2+/ISH-)乳腺癌成人患者;3.经EGFR-TKI和含铂化疗进展的EGFR突变阳性非鳞状NSCLC;4.经EGFR-TKI治疗后进展的EGFR突变阳性非鳞状NSCLC成人患者。

Commercial Insurance List

Not Listed

Not listed in the 2025 or 2026 NHSA Commercial Health Insurance Innovative Drug List.

2025 vs 2026 NRDL Payment Scope Comparison

2025 NRDL · #252NHSA · PDF p.163

Restricted to 2 indications: (1) ≥3L unresectable/metastatic TNBC; (2) EGFR-mutated locally advanced/metastatic non-squamous NSCLC after both EGFR-TKI and platinum-based chemotherapy.

限:1.既往至少接受过2种系统治疗(其中至少1种治疗针对晚期或转移性阶段)的不可切除的局部晚期或转移性三阴性乳腺癌成人患者;2.经表皮生长因子受体(EGFR)酪氨酸激酶抑制剂(TKI)和含铂化疗治疗后进展的EGFR基因突变阳性的局部晚期或转移性非鳞状非小细胞肺癌(NSCLC)成人患者。

2026 NRDL · #284NHSA · PDF p.147

Expanded to 4 indications: (1) ≥3L TNBC; (2) HR+/HER2- unresectable/metastatic BC post-ET and ≥1L chemo; (3) EGFR-mutated non-squamous NSCLC post-EGFR-TKI and platinum chemo; (4) Earlier-line EGFR-mutated non-squamous NSCLC post-EGFR-TKI alone.

限:1.既往至少接受过2种系统治疗的不可切除局部晚期或转移性三阴性乳腺癌成人患者;2.既往接受过内分泌治疗且在晚期阶段接受过至少一线化疗的不可切除或转移性HR阳性HER2阴性(IHC 0、1+或2+/ISH-)乳腺癌成人患者;3.经EGFR-TKI和含铂化疗进展的EGFR突变阳性非鳞状NSCLC;4.经EGFR-TKI治疗后进展的EGFR突变阳性非鳞状NSCLC成人患者。

Approved Products, Dosage Forms & Approval Numbers

1 verified NMPA record
Approval No.Dosage Form & StrengthEvent & ScopeApproval / Notice DateMAH & Source
国药准字S20240052
Powder for Injection (注射剂)
200mg/瓶
Initial Approval

Adult patients with unresectable locally advanced or metastatic triple-negative breast cancer (TNBC) who have received at least two prior systemic therapies (at least one in the advanced or metastatic setting).

用于既往至少接受过2种系统治疗(其中至少1种治疗针对晚期或转移性阶段)的不可切除的局部晚期或转移性三阴性乳腺癌成人患者。

Approved: 2024-11-27
Published: 2024-11-27
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.

Change Timeline

  1. (2027-01-01)Basic NRDL· Catalog published: Nov 14, 2026

    2026 NRDL · Payment Scope Updated

    Expanded from 2 indications in 2025 (#252) to 4 indications in 2026 (#284), adding HR+/HER2- breast cancer (post-ET/chemo) and earlier post-EGFR-TKI non-squamous NSCLC.

    Chinese original: 支付范围由2025版2项扩增至4项,新增HR+/HER2-乳腺癌及经EGFR-TKI治疗进展后的EGFR突变非鳞状NSCLC(无需先经含铂化疗)。

    NHSA · PDF p.147Verified 2026-11-20
  2. (2024-11-27)NMPA Approval

    NMPA Initial Marketing Approval (国药准字S20240052 · 200mg/瓶)

    Adult patients with unresectable locally advanced or metastatic triple-negative breast cancer (TNBC) who have received at least two prior systemic therapies (at least one in the advanced or metastatic setting).

    Chinese original: 用于既往至少接受过2种系统治疗(其中至少1种治疗针对晚期或转移性阶段)的不可切除的局部晚期或转移性三阴性乳腺癌成人患者。

Verified Names & Aliases

Every English INN, Chinese generic name, brand name, and R&D code is recorded with its source.

注射用芦康沙妥珠单抗dosage name(NHSA)
SKB264code(WHO)
sac-TMTcode(WHO)
佳泰莱brand zh(NMPA)

Primary Sources for This Record